Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.43 |
| ▸ | TCF7L2 | Q9NQB0 | 4/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5028710 | 0.99 | NCF1 (0.48) | NCF1MEN1KMT2AHRH4CTNNB1 | |
| SCHEMBL5024388 | 0.88 | CTNNB1 (0.49) | NCF1MEN1KMT2ACTNNB1TCF7L2 | |
| SCHEMBL5024554 | 0.88 | NCF1 (0.51) | NCF1MEN1KMT2ACTNNB1TCF7L2 | |
| SCHEMBL5028716 | 0.87 | NCF1 (0.50) | NCF1MEN1KMT2ACTNNB1TCF7L2 | |
| SCHEMBL5516708 | 0.87 | NCF1 (0.46) | NCF1MEN1KMT2A | |
| SCHEMBL5026871 | 0.86 | NPC1 (0.52) | NCF1MEN1KMT2ACTNNB1TCF7L2 | |
| SCHEMBL5024595 | 0.84 | RAB9A (0.54) | NCF1MEN1KMT2A | |
| SCHEMBL5022553 | 0.84 | NCF1 (0.51) | NCF1MEN1KMT2ACTNNB1TCF7L2 | |
| SCHEMBL5024451 | 0.83 | NCF1 (0.46) | NCF1MEN1KMT2AHRH4CACNA1B | |
| SCHEMBL5026888 | 0.82 | NCF1 (0.50) | NCF1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474145-B1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-23 | — | — | EP | disclosed |
| CN-1627945-A | Quinoline derivatives as NPY antagonists | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | CN | disclosed |
| EP-1474145-A1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-6696467-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030153553-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | US | disclosed |
| WO-2003066055-A1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153553-A1 | Quinoline derivatives | NPY1R, NPY4R, GLP1R | NCF1 1858/4885MEN1 339/4885KMT2A 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.